The most common genetic killer of infants, a disease known as spinal muscular atrophy, is caused by mutations in a single gene. The human genome contains its own backup system—near-identical copies of the defective gene—yet these secondary sequences rarely get used correctly. As Elie Dolgin finds out, drug companies hope to change that, with the first wave of targeted therapies that reboot the body's backup system now entering clinical trials.
This is a preview of subscription content
Access options
Subscribe to Journal
Get full journal access for 1 year
68,37 €
only 5,70 € per issue
Tax calculation will be finalised during checkout.
Buy article
Get time limited or full article access on ReadCube.
$32.00
All prices are NET prices.
Change history
11 January 2013
The article entitled "Call in the backup" in the November 2012 issue (Nat. Med. 18, 1602–1606, 2012) misspelled Rajesh Ranganathan's first name as Rajan. The error has been corrected in the HTML and PDF versions of the article.
References
Swoboda, K.J. et al. PLoS One 5, e12140 (2010).
Kissel, J.T. et al. PLoS One 6, e21296 (2011).
Passini, M.A. et al. Sci. Transl. Med. 3, 72ra18 (2011).
Butchbach, M.E. et al. Hum. Mol. Genet. 19, 454–467 (2010).
Hua, Y. et al. Nature 478, 123–126 (2011).
Porensky, P.N. et al. Hum. Mol. Genet. 21, 1625–1638 (2012).
Foust, K.D. et al. Nat. Biotechnol. 28, 271–274 (2010).
Author information
Affiliations
Rights and permissions
About this article
Cite this article
Dolgin, E. Call in the backup. Nat Med 18, 1602–1605 (2012). https://doi.org/10.1038/nm1112-1602
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm1112-1602
Further reading
-
Corrections
Nature Medicine (2013)
-
Biotech comes to its 'antisenses' after hard-won drug approval
Nature Medicine (2013)
-
Corrections
Nature Medicine (2012)